About ensysce biosciences inc - ENSC
Ensysce Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of solutions for severe pain relief while reducing the fear of and the potential for misuse and overdose. The firm's Trypsin Activated Abuse Protection and Multi-Pill Abuse Resistance platforms are in the process of developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. The company was founded in April 2003 and is headquartered in La Jolla, CA.
ENSC At a Glance
Ensysce Biosciences, Inc.
7946 Ivanhoe Avenue
La Jolla, California 92037
| Phone | 1-858-263-4196 | Revenue | 5.07M | |
| Industry | Biotechnology | Net Income | -10,175,700.00 | |
| Sector | Health Technology | Employees | 10 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
ENSC Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 0.464 |
| Price to Book Ratio | 1.31 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.196 |
| Enterprise Value to Sales | -0.396 |
| Total Debt to Enterprise Value | -0.14 |
ENSC Efficiency
| Revenue/Employee | 506,665.00 |
| Income Per Employee | -1,017,570.00 |
| Receivables Turnover | 12.054 |
| Total Asset Turnover | 0.777 |
ENSC Liquidity
| Current Ratio | 1.586 |
| Quick Ratio | 1.586 |
| Cash Ratio | 0.944 |
ENSC Profitability
| Gross Margin | N/A |
| Operating Margin | -202.125 |
| Pretax Margin | -200.846 |
| Net Margin | -200.837 |
| Return on Assets | -155.953 |
| Return on Equity | -294.004 |
| Return on Total Capital | -291.261 |
| Return on Invested Capital | -294.004 |
ENSC Capital Structure
| Total Debt to Total Equity | 8.711 |
| Total Debt to Total Capital | 8.013 |
| Total Debt to Total Assets | 3.756 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |